According to the company, new clinical data for the mRNA-1273.214 vaccine it is developing against the BA.1 variant showed significantly higher neutralizing antibody responses against the rapidly spreading BA.4 and BA.5 compared to the current booster doses.
The pharmaceutical and biotech company Modern announced today that is developing two updated vaccines against the Omicron variant for the fall of the coronavirus: one designed against the BA.1 subvariant and another against the BA.4 and BA.5 subvariants.
Vaccine makers including Moderna and Pfizer are developing updated vaccines against Omicron’s rapidly spreading BA.4 and BA.5 subvariants, which have been spreading in the United States in recent weeks.
The bivalent vaccines are designed to target two different variants of the coronavirus: the original one from 2020 and the newer ones brought to the fore by Omicron.
According to Moderna, the new clinical data for the mRNA-1273,214 vaccine it is developing against the BA.1 variant, showed significantly higher neutralizing antibody responses against the rapidly circulating BA.4 and BA.5 compared to the present booster doses.
The company’s second vaccine, mRNA-1273.222, targets the BA.4/5 strains and is being developed in accordance with recent US Food and Drug Administration (FDA) recommendations.
RES-EMP
View the news feed and get the latest news.
